Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=518 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Migraine
Primary: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose — 121; 190 Participants — p=<.0001
N/A N=19 Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Breast Neoplasm · Physical Activity
Primary: Acceptability: Percent of Eligible Patients That Provide Consent and Are Enrolled in the Study. — 19 Participants
Phase 3 N=178 A Study of Paliperidone Palmitate 6-Month Formulation
Schizophrenia
Primary: Number of Participants With Relapse — 7 Participants
N/A N=90 Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus
Gestational Diabetes Mellitus
Primary: The Concentration of Serum FGF19 — 65.96; 124.47 pg/mL
N/A N=23 Open Trial of a Behavioral Activation Telepsychology Intervention for People Who Inject Drugs
Intravenous Drug Usage
Primary: Change in Behavioral Activation Assessed With Behavioral Activation for Depression Scale (BADS) Score — 77.00; 86.75; 69.67 score on a scale — p=0.06
N/A N=36 Voice Treatment for Parkinson's Disease
Idiopathic Parkinson Disease
Primary: Treatment-related Changes in Vocal Intensity Will be Assessed Using Acoustic Analysis. — 3; 3; 0.26 Decibels
Phase 2 N=95 Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Hepatocellular Carcinoma
Primary: Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment — 5.9; 11.1; 7.4; 14.8 Percentage of participants
N/A N=10 Feasibility Clinical Investigation Using the InPress Device for the Treatment of Postpartum Hemorrhage
Post Partum Hemorrhage
Primary: Number of Related SAE — 0 SAEs
Phase 2 N=122 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
Covid19
Primary: For Viral Domain: Change in Viral Shedding — 1.6; 1.7; 1.0 cycles — p=0.20
Phase 3 N=255 Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
Anesthesia
Primary: Number of Participants With Successful Anesthesia Induction — 163; 81 Participants
Phase 1 N=99 Encouraging Cognitive Screenings at African American Churches
Dementia · Healthy
Primary: Number of Participants Who Received a Cognitive Screening — 5; 11 Participants
Phase 2 N=12 Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Acute Myeloid Leukemia · Higher Risk Myelodysplastic Syndrome
Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants
N/A N=29 Texting for Mobility in Overweight/Obese Adults With Peripheral Artery Disease
Overweight and Obesity
Primary: Walking Distance — 331.19; 298.67 meters
Phase 2 N=307 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Corneal Endothelial Cell Loss · Ocular Pain · Ocular Inflammation
Primary: Change From Baseline in Central Corneal Endothelial Cell Counts — -243.4; -184.8; -260.3 cells/mm^2 — p=0.4529